Overweight, obesity increase risk of cardiotoxicity from anthracyclines
Being overweight or obese was significantly associated with a greater risk of developing cardiotoxicity among breast cancer patients treated with anthracyclines and/or trastuzumab, investigators...
Source: Ob.Gyn. News - Category: OBGYN Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Eating Disorders & Weight Management | Heart | Herceptin | Obesity | OBGYN